Common Stock, par value $0.001 per share
- Symbol
- ARTL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Artelo Biosciences, Inc.
ARTLNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
ITEM 5.07 Submission of Matters to a Vote of Security Holders. We held our Annual Meeting of Stockholders (the “Annual Meeting”) on July 17, 2026. Of the 2,848,540 shares of our common stock, par value $0.001 (“Common Stock”), outstanding as of the record date of May 22, 2026, 1,172,203 shares of Common Stock were represented at the Annual Meeting, either by proxy or by attending the virtual annua…
Company context
We are currently developing a novel, benzimidazole dual cannabinoid (CB) agonist that targets both the CB1 and CB2 peripheral receptors. This synthetic small molecule program is a G protein-coupled receptor (“GPCR”) designated ART27.13 and was initially developed by AstraZeneca plc. We are developing ART27.13 as a potential treatment for cancer-related anorexia and it is currently in a Phase 1b/2a trial, titled the Cancer Appetite Recovery Study (“CAReS”). In an interim analysis of the on-going Phase 2a CAReS trial, patients with cancer anorexia receiving ART27.13 demonstrated a mean weight gain of over 6% compared to a 5% loss in the placebo group, while maintaining a safety profile similar to the Phase 1b despite doses up to twice the previous maximum. Currently there is no FDA approved treatment for cancer anorexia cachexia syndrome.
Current securities
Registered securities in this filing
ARTELO BIOSCIENCES, INC. · 8-K · Filed 2026-07-17
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
ITEM 5.07 Submission of Matters to a Vote of Security Holders.
We held our Annual Meeting of Stockholders (the “Annual Meeting”) on July 17, 2026. Of the 2,848,540 shares of our common stock, par value $0.001 (“Common Stock”), outstanding as of the record date of May 22, 2026, 1,172,203 shares of Common Stock were represented at the Annual Meeting, either by proxy or by attending the virtual annual meeting, constituting, of the shares entitled to vote, approximately 41.2% of the outstanding shares of Common Stock. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below.
Election of Three Class III Directors. The following nominees were re-elected by the holders of our common stock to serve as our Class III directors until our 2029 annual meeting of stockholders and until their successors have been duly elected and qualified:
Nominee For Withhold Broker Non-Votes
───────────────────────────────────────────────────────────────────────────────────
Gregory R. Reyes, M.D., Ph. D. 179,416 55,405 937,382
Tamara A. Favorito 176,821 58,000 937,382
Gregory D. Gorgas 171,567 63,254 937,382
Approval of an Amendment to the Articles of Incorporation. The amendment to our Articles of Incorporation, as amended, to increase the number of authorized shares of our common stock from 166,666,667 to 500,000,000 was approved based on the following results of voting:
For Against Abstain
─────────────────────────────────────
985,717 164,845 21,641
Share Issuance Approval. The issuance of more than 20% of our issued and outstanding common stock pursuant to our Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5 was approved based on the following results of voting:
For Against Abstain Broker Non-Votes
──────────────────────────────────────────────────────────
91,158 65,155 78,508 937,382